Ranger Investment Management L.P. Has $32.54 Million Position in Repligen Co. (NASDAQ:RGEN)

Ranger Investment Management L.P. decreased its position in shares of Repligen Co. (NASDAQ:RGEN) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 226,067 shares of the biotechnology company’s stock after selling 4,324 shares during the period. Repligen comprises 2.1% of Ranger Investment Management L.P.’s holdings, making the stock its 15th largest holding. Ranger Investment Management L.P. owned approximately 0.40% of Repligen worth $32,540,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Repligen in the fourth quarter valued at approximately $216,000. Van ECK Associates Corp grew its stake in shares of Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after buying an additional 3,066 shares during the last quarter. Stephens Investment Management Group LLC lifted its stake in shares of Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after acquiring an additional 37,057 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Repligen during the 3rd quarter valued at $233,000. 97.64% of the stock is owned by institutional investors.

Repligen Price Performance

Repligen stock opened at $108.89 on Wednesday. The business has a fifty day moving average price of $146.48 and a 200-day moving average price of $146.91. Repligen Co. has a one year low of $102.97 and a one year high of $182.52. The firm has a market capitalization of $6.11 billion, a P/E ratio of -213.51, a PEG ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price on the stock. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $178.64.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.